OBJECTIVE: To evaluate the effect of dipeptidyl-peptidase-4 (DPP-4) inhibitor vildagliptin on
high sensitivity C-reactive protein (hsCRP) and arterial stiffness (AS) in patients with type 2 …

OBJECTIVE: Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of
incretin hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major …

Type 2 diabetes mellitus is a growing problem in most parts of the world. There is now good
evidence that controlling hyperglycaemia can help prevent many of the serious …

Vildagliptin is a selective and potent dipeptidyl peptidase-4 inhibitor that improves glycemic
control by inhibiting the degradation of both endogenous glucagon-like peptide-1 and …

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug
interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus …

Inhibitors of dipeptidyl peptidase-4 (DPP-IV), a key regulator of the actions of incretin
hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major question …

Vildagliptin is an oral incretin enhancer that acts to increase active levels of the incretin
hormone glucagon‐like peptide‐1 (GLP‐1) by inhibiting the dipeptidyl peptidase‐4 enzyme …

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy
have been widely confirmed in a large body of clinical studies of up to 2 years' duration in …

Introduction: Type 2 diabetes mellitus (T2DM) is intricately allied with an increased risk of
atherothrombotic disease. Thrombosis is the cause of mortality in 80% of patients with …

Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors modulate incretin hormones
and exert anti-diabetic effects in type 2 diabetes mellitus. Treatment with angiotensin II type …